Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study
Sebastiaan N Siegerink, Steven C Kuijper, Tom van den Ende, Rob H A Verhoeven, Sjoerd G Elias, Nadia Haj Mohammad, Marije Slingerland, Sarah Derks, Hanneke W M van Laarhoven · 2026
Read Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study by Sebastiaan N Siegerink, Steven C Kuijper, Tom van den Ende, Rob H A Verhoeven, Sjoerd G Elias, Nadia Haj Mohammad, Marije Slingerland, Sarah Derks, Hanneke W M van Laarhoven (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13237275.txt.
Description
Sebastiaan N Siegerink and team used Netherlands Cancer Registry data in 2026 to compare two second-line strategies for metastatic gastroesophageal cancer. After first-line treatment with oxaliplatin combinations failed, doctors either reintroduced oxaliplatin or switched to paclitaxel with ramucirumab. The team emulated a randomized trial by weighting 129 patients so the groups resembled each other.
Overall survival did not differ clearly between the strategies, with medians of about nine months for reintroduction and eight months for the switch. Patients who reused oxaliplatin more often went on to further treatment lines afterward. The authors propose reintroduction as a sound option for selected patients after a long first response. A true randomized trial remains absent.
Catalog record
| CREATOR | Sebastiaan N Siegerink, Steven C Kuijper, Tom van den Ende, Rob H A Verhoeven, Sjoerd G Elias, Nadia Haj Mohammad, Marije Slingerland, Sarah Derks, Hanneke W M van Laarhoven |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |